ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,634.61
1.15%
US Tech 100
19,202.80
1.10%
Dow Jones
41,175.08
1.14%
Brent Oil
78.375
0.00%
Bitcoin
64,385.20
0.34%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Revance Therapeutics Inc (RVNC)

  7. Revance Therapeutics Inc (RVNC) News

RVNC

Revance Therapeutics (RVNC)

Revance Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:RVNC
DateTimeSourceHeadlineSymbolCompany
08/13/20249:29AMEdgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:RVNCRevance Therapeutics Inc
08/12/20245:18PMEdgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:RVNCRevance Therapeutics Inc
08/12/20243:18PMPR Newswire (US)ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Revance Therapeutics, Inc.NASDAQ:RVNCRevance Therapeutics Inc
08/12/20249:20AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
08/12/20248:00AMPR Newswire (US)Crown Laboratories and Revance Announce Entry Into Merger AgreementNASDAQ:RVNCRevance Therapeutics Inc
08/09/20249:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
08/08/20244:34PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RVNCRevance Therapeutics Inc
08/08/20244:07PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
08/08/20244:05PMBusiness WireRevance Reports Second Quarter 2024 Financial Results, Provides Corporate UpdateNASDAQ:RVNCRevance Therapeutics Inc
08/01/20244:05PMBusiness WireRevance to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024NASDAQ:RVNCRevance Therapeutics Inc
06/14/20244:05PMBusiness WireRevance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RVNCRevance Therapeutics Inc
05/28/20244:05PMBusiness WireRevance to Participate in Upcoming Investor ConferencesNASDAQ:RVNCRevance Therapeutics Inc
05/09/20244:33PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RVNCRevance Therapeutics Inc
05/09/20244:08PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
05/09/20244:06PMBusiness WireRevance Reports First Quarter 2024 Financial Results, Provides Corporate UpdateNASDAQ:RVNCRevance Therapeutics Inc
05/09/20244:05PMBusiness WireRevance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical DystoniaNASDAQ:RVNCRevance Therapeutics Inc
05/02/20244:05PMBusiness WireRevance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024NASDAQ:RVNCRevance Therapeutics Inc
04/12/20248:00AMBusiness WireRevance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual MeetingNASDAQ:RVNCRevance Therapeutics Inc
03/27/20244:05PMBusiness WireRevance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RVNCRevance Therapeutics Inc
03/08/20244:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
03/05/20245:08PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
03/05/20245:00PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RVNCRevance Therapeutics Inc
03/04/20245:34PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
03/04/20245:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
03/04/20244:44PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
03/04/20244:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
03/04/20249:25AMBusiness WireRevance Announces Pricing of $100.0 Million Public Offering of Common StockNASDAQ:RVNCRevance Therapeutics Inc
03/04/20246:39AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RVNCRevance Therapeutics Inc
03/04/20246:37AMBusiness WireRevance Announces Proposed Public Offering of Common StockNASDAQ:RVNCRevance Therapeutics Inc
02/29/20244:36PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:RVNC

Your Recent History

BIT
P1P3D2
BNP Paribas Issuance
BIT
X45662
Natixes Structured Issua...
BIT
UC3U4N
Unicredit Bank
BIT
F18541
Vontobel Financial Produ...
LSE
0N59
Ahlers
BIT
FLUC
Frank Temp ICAV Frank US...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved